Ryo Asakawa
Overview
Explore the profile of Ryo Asakawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
10
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Asakawa R, Yokoyama S, Yamada R, Maeda S, Ohto T, Tada H, et al.
J Am Chem Soc
. 2024 Aug;
146(33):23529-23536.
PMID: 39133559
Realizing efficient long-distance intramolecular charge transport based on a hopping mechanism is a key challenge in molecular electronics. In hopping transport, a smaller reorganization energy (λ) and energy difference between...
2.
Tanaka S, Yoshimura N, Asakawa R, Tobita S, Yaga M, Ueno K
Medicine (Baltimore)
. 2024 Jul;
103(30):e39094.
PMID: 39058830
Rationale: Extracorporeal membrane oxygenation (ECMO) is the last trump card for severe respiratory failure. The main complications of ECMO are bleeding and thrombosis, both of which can be life-threatening. Large...
3.
Tanaka S, Yoshimura N, Asakawa R, Tobita S, Yaga M, Ueno K
Thorac Cancer
. 2023 Jul;
14(25):2618-2621.
PMID: 37488715
Previously, cytotoxic drugs were the only option for patients with non-small cell lung cancer (NSCLC) and the prognosis was poor. However, molecularly targeted therapies and immune checkpoint inhibitors represent a...
4.
Tanaka S, Takayama Y, Kitou R, Asakawa R, Tobita S, Ike A, et al.
Clin Case Rep
. 2022 Dec;
10(12):e6754.
PMID: 36567689
Coronavirus disease 2019 (COVID-19) has become a worldwide outbreak, and it can cause various symptoms and complications. However, pneumothorax secondary to COVID-19 is relatively uncommon. We herein report a 60-year-old...
5.
Tanaka S, Komuta K, Asakawa R, Tanizaki S, Kanai T, Uchida J, et al.
J Bronchology Interv Pulmonol
. 2022 Jun;
29(3):e31-e33.
PMID: 35730781
No abstract available.
6.
Tanaka S, Asakawa R, Komuta K, Tanizaki S, Kanai T, Kuroyama M, et al.
Respir Med Case Rep
. 2020 Nov;
31:101266.
PMID: 33134073
Immune checkpoint inhibitors (ICIs) improved the prognosis of patients with advanced lung cancers. The combination therapy of cytotoxic drugs and ICI is approved as first-line chemotherapy in non-small-cell lung cancer...